A vaccine given during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can range from causing mild, cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by activating the mother’s body’s defences to produce defence proteins, which are then passed to the developing baby through the placenta. This mother-derived protection offers newborns with immediate protection from the moment of birth, precisely when they are most vulnerable to RSV. The latest research shows that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence suggesting that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to have the vaccine on schedule, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85% coverage when vaccinated four weeks before birth
- Maternal antibodies transferred through the placenta protect newborns from birth
- Protection achievable with 2-week gap before early delivery
- Vaccination during the third trimester still provides meaningful infant protection
Compelling evidence from recent research
The performance of the pregnancy RSV vaccine has been demonstrated through a thorough investigation undertaken in England, examining data from close to 300,000 babies born between September 2024 and March 2025. This accounts for approximately nine out of ten of all births during that six-month timeframe, providing robust and representative information of the vaccine’s actual performance. The study’s results have been endorsed by the UK Health Security Agency as showing robust protection for newborns during their earliest and most vulnerable period. The breadth of this investigation offers healthcare professionals and expectant parents with assurance in the vaccine’s established performance across diverse populations and circumstances.
The results paint a compelling picture of the vaccine’s protective power. More than 4,500 babies were hospitalised with RSV during the study period, with the great majority being infants whose mothers had not received the vaccination. This marked difference highlights the vaccine’s essential role in protecting against serious illness in newborns. The drop in hospital admissions exceeding 80 per cent represents a major public health success, potentially preventing thousands of infants from experiencing the distressing and potentially serious symptoms associated with severe RSV infection. These findings support the importance of the vaccination programme launched in the UK in 2024.
Research approach and coverage
The research reviewed birth and hospital admission records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection levels and hospital admissions. The substantial sample size and comprehensive nature of the data collection ensured that findings were statistically robust and representative of the broader population, rather than isolated cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at differing periods before delivery. This allowed researchers to establish the least amount of time between vaccination and birth for maximum protection, as well as to determine whether protection stayed significant with shorter intervals. The methodology measured actual clinical results rather than controlled laboratory conditions, providing practical evidence of how the vaccine performs when delivered across diverse clinical settings and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Learning about RSV and the threats
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity changing substantially from minor cold-type symptoms to serious, potentially fatal chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during peak seasons.
The infection causes inflammation deep within the lungs and airways, making it perilously hard for affected infants to breathe and feed properly. Parents frequently observe their babies fighting for breath, their chests heaving as they attempt to draw adequate oxygen into their weakened respiratory system. Whilst most newborns get better with clinical support, a modest yet notable proportion perish from RSV-related complications each year, making vaccination as prevention a critical public health priority for protecting the youngest and most vulnerable members of society.
- RSV produces lung inflammation, causing severe breathing difficulties in babies
- Half of all infants catch the virus in their first few months of life
- Symptoms span from mild colds to life-threatening chest infections requiring hospitalisation
- Over 20,000 UK babies require serious hospital care for RSV each year
- Few babies die from RSV complications annually in the UK
Take-up rates and expert recommendations
Since the RSV vaccine programme launched in 2024, health officials have highlighted the importance of pregnant women receiving their jab at the ideal time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has stressed that timing matters greatly for guaranteeing newborns receive the strongest possible immunity from birth. Whilst the research shows that vaccination performed at least four weeks prior to delivery delivers approximately 85% protection, experts advise women to get their vaccine as soon as feasible from 28 weeks of pregnancy forward to enhance the antibodies transferred to their babies through the placenta.
The guidance from public health bodies remains clear: pregnant women should make a priority of vaccination during their final three months, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has reassured pregnant women that protection remains still achievable with reduced timeframes between vaccination and birth, including even a fourteen-day window for those giving birth ahead of schedule. This flexible approach recognises the realities of pregnancy and childbirth whilst ensuring strong safeguarding for vulnerable newborns during their most critical early months when RSV poses the greatest risk of severe infection.
Regional disparities in immunisation
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and implementation timelines have varied across different regions and NHS trusts. Some areas have achieved higher vaccination coverage among qualifying expectant mothers, whilst others remain focused to boost understanding and access to the jab. These geographical variations reflect variations in medical facilities, engagement approaches, and local engagement efforts, though the national data shows robust and reliable protection irrespective of geographical location.
- NHS trusts rolling out diverse outreach initiatives to engage with pregnant women
- Geographic variations in vaccine uptake rates across England necessitate strategic intervention
- Local healthcare systems adapting programmes to meet specific population needs
Practical implications and parental perspectives
The vaccine’s remarkable effectiveness provides tangible benefits for families throughout the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV prior to the introduction of this safeguarding intervention, the 80% drop in admissions means thousands of infants spared from serious illness. Parents no longer face the upsetting situation of watching their newborns gasping for air or difficulty feeding, symptoms that characterise serious RSV disease. The vaccine has fundamentally shifted the terrain of neonatal respiratory health, providing expectant mothers a preventative option to safeguard their youngest infants during those vital initial period.
For families like that of Malachi, whose severe RSV infection led to devastating brain damage, the vaccine’s introduction carries profound emotional significance. His mother’s support of the jab underscores the transformative consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates powerfully with parents now given protection. The knowledge that such grave complications—hospital stay, oxygen dependency, neurological damage—are now largely preventable has given considerable reassurance to women in pregnancy navigating their third trimester, transforming what was once an unavoidable seasonal threat into a manageable health risk.